Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 278

Similar articles for PubMed (Select 11927833)

1.
2.

Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.

Li J, Wang XR, Zhai XW, Wang HS, Qian XW, Miao H, Zhu XH.

Int J Clin Exp Med. 2015 Apr 15;8(4):6109-13. eCollection 2015.

3.

Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?

Lima A, Bernardes M, Azevedo R, Medeiros R, Seabra V.

Int J Mol Sci. 2015 Jun 16;16(6):13760-80. doi: 10.3390/ijms160613760.

4.

Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.

Chaabane S, Marzouk S, Akrout R, Ben Hamad M, Achour Y, Rebai A, Keskes L, Fourati H, Bahloul Z, Maalej A.

Eur J Drug Metab Pharmacokinet. 2015 Jun 16. [Epub ahead of print]

PMID:
26077125
5.

A Case of Diverticular Perforation in a Young Patient with Rheumatoid Arthritis on Methotrexate.

Chang I, Guggenheim C, Laird-Fick H.

Case Rep Med. 2015;2015:617268. doi: 10.1155/2015/617268. Epub 2015 Apr 29.

6.
7.

Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.

Jabeen S, Holmboe L, Alnæs GI, Andersen AM, Hall KS, Kristensen VN.

Pharmacogenomics J. 2015 Mar 17. doi: 10.1038/tpj.2015.11. [Epub ahead of print]

PMID:
25778468
8.

[Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity.]

Borman P, Taşbaş Ö, Karabulut H, Tukun A, Yorgancıoğlu R.

Rev Bras Reumatol. 2015 Jan 28. pii: S0482-5004(15)00017-0. doi: 10.1016/j.rbr.2014.12.001. [Epub ahead of print] Portuguese.

9.

The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.

Soukup T, Dosedel M, Pavek P, Nekvindova J, Barvik I, Bubancova I, Bradna P, Kubena AA, Carazo AF, Veleta T, Vlcek J.

Rheumatol Int. 2015 Jul;35(7):1149-61. doi: 10.1007/s00296-015-3219-z. Epub 2015 Jan 25.

PMID:
25618758
10.

Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.

Świerkot J, Ślęzak R, Karpiński P, Pawłowska J, Noga L, Szechiński J, Wiland P.

Pol Arch Med Wewn. 2015;125(3):152-61. Epub 2015 Jan 19.

11.

Methylene tetrahydrofolate reductase genotypes frequencies: association with the toxicity of and response to methotrexate in rheumatoid arthritis patients.

Saleh MM, Irshaid YM, Mustafa KN.

Int J Clin Pharmacol Ther. 2015 Feb;53(2):154-62. doi: 10.5414/CP202242.

PMID:
25492850
12.

Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.

Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, Ong TC, Mohamed Z.

Pharmacogenomics. 2014 Aug;15(11):1479-94. doi: 10.2217/pgs.14.97.

13.

Is there a role for the MTHFR 677C>T and 1298A>C polymorphisms in methotrexate-induced liver toxicity?

te Loo DM, Hagleitner MM, Coenen MJ.

Pharmacogenomics. 2014 Aug;15(11):1401-3. doi: 10.2217/pgs.14.82. No abstract available.

14.

Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.

Lima A, Seabra V, Bernardes M, Azevedo R, Sousa H, Medeiros R.

PLoS One. 2014 Oct 3;9(10):e108165. doi: 10.1371/journal.pone.0108165. eCollection 2014.

15.

The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with non-Hodgkin malignant lymphoma.

Erculj N, Kotnik BF, Debeljak M, Jazbec J, Dolzan V.

Radiol Oncol. 2014 Jul 10;48(3):289-92. doi: 10.2478/raon-2013-0076. eCollection 2014 Sep.

16.

Laboratory biomarkers for guiding therapy with methotrexate in rheumatoid arthritis.

Abud-Mendoza C, Martínez-Martínez MU, Monsiváis-Urenda A, González-Amaro R.

Curr Pharm Des. 2015;21(2):202-11.

PMID:
25163739
17.

SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.

Lima A, Bernardes M, Azevedo R, Monteiro J, Sousa H, Medeiros R, Seabra V.

Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.

PMID:
25124723
18.

Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?

Salazar J, Moya P, Altés A, Díaz-Torné C, Casademont J, Cerdà-Gabaroi D, Corominas H, Baiget M.

Pharmacogenomics. 2014 Jun;15(8):1079-90. doi: 10.2217/pgs.14.67.

PMID:
25084201
19.

Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.

Samara SA, Irshaid YM, Mustafa KN.

Int J Clin Pharmacol Ther. 2014 Sep;52(9):746-55. doi: 10.5414/CP202098.

PMID:
25074866
20.

Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.

Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V, Medeiros R.

Biomed Res Int. 2014;2014:368681. doi: 10.1155/2014/368681. Epub 2014 May 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk